Bacil Pharma (BOM:524516) Debt-to-Equity : 0.08 (As of Mar. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Bacil Pharma Debt-to-Equity?

Bacil Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹0.98 Mil. Bacil Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹0.00 Mil. Bacil Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹12.13 Mil. Bacil Pharma's debt to equity for the quarter that ended in Mar. 2024 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bacil Pharma's Debt-to-Equity or its related term are showing as below:

BOM:524516' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.05 Max: 0.13
Current: 0.08

During the past 13 years, the highest Debt-to-Equity Ratio of Bacil Pharma was 0.13. The lowest was 0.02. And the median was 0.05.

BOM:524516's Debt-to-Equity is ranked better than
75.12% of 844 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs BOM:524516: 0.08

Bacil Pharma Debt-to-Equity Historical Data

The historical data trend for Bacil Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bacil Pharma Debt-to-Equity Chart

Bacil Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.12

0.13

0.03

0.02

0.08

Bacil Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.02	N/A	0.03	N/A	0.08

Competitive Comparison of Bacil Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Bacil Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bacil Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bacil Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bacil Pharma's Debt-to-Equity falls into.

Bacil Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bacil Pharma's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.984	+	0)	/	12.131
	=	0.08

Bacil Pharma's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.984	+	0)	/	12.131
	=	0.08

Bacil Pharma (BOM:524516) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bacil Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bacil Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bacil Pharma (BOM:524516) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bacil Pharma Ltd (BOM:524516) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

Sir P. M. Road, No. 71, Laxmi Building, 4th Floor, Fort, Mumbai, MH, IND, 400 001

Website

https://www.bacilpharma.co.in

Bacil Pharma Ltd is an Indian-based pharmaceutical company operating in a single segment. It is engaged in the manufacturing of pharmaceuticals, medicinal chemicals, and botanical products. The company manufactures, exports, supplies, and retail Anti Anxiety Medicine, Antihistamines, Chemical Compound, Drugs and Herbal Tablets, and Capsules.

Bacil Pharma (BOM:524516) Headlines

No Headlines